Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy

American Journal of Medicine

Volumn 129, Issue 11, 2016, Pages 1198-1204

  Barra, Megan E ^a   Fanikos, John ^a   Connors, Jean M ^a   Sylvester, Katelyn W ^a   Piazza, Gregory ^b   Goldhaber, Samuel Z ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Dose reduction; Drug interactions; Renal dysfunction; Venous thromboembolism

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CREATININE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MANUFACTURE; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HEMOPTYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; BLOOD; CHEMICALLY INDUCED; COMORBIDITY; COMPLICATION; DOSE RESPONSE; MIDDLE AGED; RENAL INSUFFICIENCY; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ASPIRIN; ATRIAL FIBRILLATION; COMORBIDITY; CREATININE; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; PYRIDONES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; VENOUS THROMBOEMBOLISM;

EID: 85003422084     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.05.041     Document Type: Article

References (21)

1. Mega, J.L., Simon, T., Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet 386 (2015), 281–291.
2. January, C.T., Wann, L.S., Alpert, J.S., et al., ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130 (2014), 2071–2104.
3. Verheugt, F.W.A., Granger, C.B., Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 386 (2015), 303–310.
4. Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:9921 (2014), 955–962.
5. Van der Hulle, T., Kooiman, J., Den Exter, P.L., et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12:7 (2014), 1116–1120.
6. Kearon, C., Akl, E.A., Ornelas, J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:2 (2016), 315–352.
7. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2012.
8. Xarelto [package insert]. Gurabo, PR: Janssen Pharmaceuticals, Inc; 2012.
9. Eliquis [package insert]. Princeton, NJ: Bristol-Meyers Squibb, Inc; 2012.
10. Heidbuchel, H., Verhamme, P., Alings, M., et al. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:5 (2013), 625–651.
11. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:12 (2009), 1139–1151.
12. Granger, C.B., Alexander, J.H., McMurray, J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:11 (2011), 981–992.
13. Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:10 (2011), 883–891.
14. Bauersachs, R., Berkowitz, S.D., Brenner, B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:26 (2010), 2499–2510.
15. Buller, H.R., Prins, M.H., Lensing, A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:14 (2012), 1287–1297.
16. Agnelli, G., Buller, H.R., Cohen, A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:9 (2013), 799–808.
17. Schulman, S., Kearon, C., Kakkar, A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:24 (2009), 2342–2352.
18. Graham, D.J., Reichman, M.E., Werneche, M., et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 131 (2015), 157–164.
19. Savaysa [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc; 2015.
20. Reilly, P.A., Lehr, T., Haertter, S., et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol 63:4 (2014), 321–328.
21. Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Association between edoxaban dose, concentration, anti-factor-Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385:9984 (2015), 2288–2295.